{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,28]],"date-time":"2026-09-28T05:18:43Z","timestamp":1790572723239,"version":"4.1.0"},"reference-count":48,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2022,5,16]],"date-time":"2022-05-16T00:00:00Z","timestamp":1652659200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Psychiatry"],"abstract":"<jats:sec><jats:title>Background<\/jats:title><jats:p>Selective serotonin reuptake inhibitors (SSRIs) are the first-line pharmacotherapy for obsessive-compulsive disorder (OCD), but a large proportion of patients do not achieve remission after an adequate SSRI trial. To the best of our knowledge, there have been no well-powered randomized controlled trials (RCTs) of sequenced pharmacotherapy using pragmatic research designs. China provides a unique context for undertaking such a trial that will recruit the largest treatment-na\u00efve participants and systematically compare the efficacy of different sequenced pharmacotherapy.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>A pragmatic research design will be adopted, with <jats:italic>n<\/jats:italic> = 1,600 treatment-na\u00efve OCD patients initially treated for sertraline for 12 weeks, and with non-remitters then randomized to 5 different augmentation or switching pharmacotherapy options for another 12 weeks. The 5 arms will include: (1) treatment with higher than usual doses of sertraline, (2) switch to fluvoxamine, (3) switch to venlafaxine, (4) augmentation with memantine, and (5) augmentation with aripiprazole.<\/jats:p><\/jats:sec><jats:sec><jats:title>Discussion<\/jats:title><jats:p>China is uniquely positioned to recruit sufficiently large sample sizes of treatment-na\u00efve OCD patients to compare different pharmacotherapy options; data from the proposed trial promises to help inform current clinical practice guidelines by providing important information about optimal pharmacotherapy choice for those who demonstrate no response or response but no remission to first line pharmacotherapy.<\/jats:p><\/jats:sec><jats:sec><jats:title>Trial Registration<\/jats:title><jats:p>The trail was registered on 27 August 2020 in ClinicalTrials.gov (<jats:ext-link>https:\/\/register.clinicaltrials.gov\/<\/jats:ext-link>) (NCT04539951).<\/jats:p><\/jats:sec>","DOI":"10.3389\/fpsyt.2022.822976","type":"journal-article","created":{"date-parts":[[2022,5,16]],"date-time":"2022-05-16T14:12:39Z","timestamp":1652710359000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":5,"title":["Protocol for a Pragmatic Trial of Pharmacotherapy Options Following Unsatisfactory Initial Treatment in OCD (PROCEED)"],"prefix":"10.3389","volume":"13","author":[{"given":"Pei","family":"Wang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenjie","family":"Gu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jian","family":"Gao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Changhong","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jianqun","family":"Fang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maorong","family":"Hu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hui","family":"Xiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bin","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Na","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenxin","family":"Tang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xijin","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yanbin","family":"Jia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yi","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuqi","family":"Cheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhen","family":"Tang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Helen Blair","family":"Simpson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dan J.","family":"Stein","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhen","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2022,5,16]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1016\/S2215-0366(18)30511-X","article-title":"Prevalence of mental disorders in China: a cross-sectional. epidemiological study","volume":"6","author":"Huang","year":"2019","journal-title":"Lancet Psychiatry."},{"key":"B2","doi-asserted-by":"publisher","first-page":"19r13085","DOI":"10.4088\/JCP.19r13085","article-title":"Women are at greater risk of OCD than men: a meta-analytic review of OCD prevalence worldwide","volume":"81","author":"Fawcett","year":"2020","journal-title":"J Clin Psychiatry."},{"key":"B3","doi-asserted-by":"publisher","first-page":"1358","DOI":"10.1001\/jama.2017.2200","article-title":"Obsessive-compulsive disorder: advances in diagnosis and treatment","volume":"317","author":"Hirschtritt","year":"2017","journal-title":"JAMA."},{"key":"B4","doi-asserted-by":"publisher","first-page":"e100632","DOI":"10.1136\/gpsych-2021-100632","article-title":"The cost of obsessive-compulsive disorder (OCD) in China: a multi-center cross-sectional survey based on hospitals","volume":"34","author":"Yang","year":"2021","journal-title":"Gen Psychiatry."},{"key":"B5","doi-asserted-by":"publisher","first-page":"783","DOI":"10.1212\/01.CON.0000466666.12779.07","article-title":"Obsessive-compulsive disorder","volume":"21","author":"Drubach","year":"2015","journal-title":"Continuum."},{"key":"B6","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1037\/0002-9432.77.3.489","article-title":"Practice guideline for the treatment of patients with obsessive-compulsive disorder","volume":"164","author":"Koran","year":"2007","journal-title":"Am J Psychiatry."},{"key":"B7","doi-asserted-by":"publisher","first-page":"403","DOI":"10.1177\/0269881114525674","article-title":"Evidence-based pharmacological treatment of anxiety. disorders, post-traumatic stress disorder and obsessive-compulsive disorder: a revision of the 2005 guidelines from the British Association for Psychopharmacology","volume":"28","author":"Baldwin","year":"2014","journal-title":"J Psychopharmacol."},{"key":"B8","doi-asserted-by":"publisher","first-page":"S1","DOI":"10.1186\/1471-244X-14-S1-S1","article-title":"Canadian clinical practice guidelines for the management of anxiety, posttraumatic stress and obsessive-compulsive disorders","volume":"14","author":"Katzman","year":"2014","journal-title":"BMC Psychiatry."},{"key":"B9","volume-title":"Practice Guideline For Prevention And Treatment Of Obsessive-Compulsive Disorder","author":"Si","year":"2016"},{"key":"B10","doi-asserted-by":"publisher","first-page":"CD001765","DOI":"10.1002\/14651858.CD001765.pub3","article-title":"Selective serotonin re-uptake inhibitors (SSRIs) versus","volume":"2008","author":"Soomro","year":"2008","journal-title":"Cochrane Database Syst Rev."},{"key":"B11","doi-asserted-by":"publisher","first-page":"5647","DOI":"10.2174\/0929867325666171222163645","article-title":"Systematic review of evidence-based treatment strategies for obsessive- compulsive disorder resistant to first-line pharmacotherapy","volume":"25","author":"Albert","year":"2018","journal-title":"Curr Med Chem."},{"key":"B12","doi-asserted-by":"publisher","first-page":"269","DOI":"10.4088\/JCP.v67n0214","article-title":"Response versus remission in obsessive-compulsive disorder","volume":"67","author":"Simpson","year":"2006","journal-title":"J Clin Psychiatry."},{"key":"B13","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1097\/YIC.0b013e3283613e4d","article-title":"Excluding the typical patient: thirty years of. pharmacotherapy efficacy trials for obsessive-compulsive disorder","volume":"26","author":"Odlaug","year":"2014","journal-title":"Ann Clin Psychiatry."},{"key":"B14","doi-asserted-by":"publisher","first-page":"1007","DOI":"10.1093\/ijnp\/pyy079","article-title":"From treatment response to recovery: a realistic goal in OCD","volume":"21","author":"Burchi","year":"2018","journal-title":"Int J Neuropsychopharmacol."},{"key":"B15","doi-asserted-by":"publisher","first-page":"685","DOI":"10.4088\/JCP.12m07789","article-title":"Treatment response, symptom remission, and wellness. in obsessive-compulsive disorder","volume":"74","author":"Farris","year":"2013","journal-title":"J Clin Psychiatry."},{"key":"B16","doi-asserted-by":"publisher","first-page":"251","DOI":"10.1002\/da.21935","article-title":"The RDoC project: a new paradigm for investigating the pathophysiology of anxiety","author":"Simpson","year":"2012","journal-title":"Depress Anxiety."},{"key":"B17","volume-title":"Diagnostic and Statistical Manual of Mental Disorders","year":"2013"},{"key":"B18","doi-asserted-by":"publisher","first-page":"1006","DOI":"10.1001\/archpsyc.1989.01810110048007","article-title":"The yale-brown obsessive compulsive scale I development, use, and reliability","volume":"46","author":"Goodman","year":"1989","journal-title":"Arch Gen Psychiatry."},{"key":"B19","first-page":"22","article-title":"The Mini-International Neuropsychiatric Interview. (M.I.N.I.): the development and validation of a structured diagnostic psychiatric interview for DSM-IV and ICD-10","volume":"59","author":"Sheehan","year":"1998","journal-title":"J Clin Psychiatry."},{"key":"B20","doi-asserted-by":"publisher","first-page":"1274","DOI":"10.1007\/s11695-015-1877-2","article-title":"Comparing the beck depression inventory-II (BDI-II) and patient health questionnaire (PHQ-9) depression measures in an outpatient bariatric clinic","author":"Schutt","year":"2016","journal-title":"Obes Surg."},{"key":"B21","doi-asserted-by":"publisher","first-page":"485","DOI":"10.1037\/1040-3590.14.4.485","article-title":"The obsessive-compulsive inventory: development and validation of a short version","volume":"14","author":"Foa","year":"2002","journal-title":"Psychol Assess."},{"key":"B22","doi-asserted-by":"publisher","first-page":"893","DOI":"10.1037\/0022-006X.56.6.893","article-title":"An inventory for measuring clinical anxiety: psychometric properties","volume":"56","author":"Beck","year":"1988","journal-title":"J Consult Clin Psychol."},{"key":"B23","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1097\/00004850-199606003-00015","article-title":"The measurement of disability","volume":"11","author":"Sheehan","year":"1996","journal-title":"Int Clin Psychopharmacol"},{"key":"B24","doi-asserted-by":"publisher","first-page":"103","DOI":"10.12809\/eaap1832","article-title":"Validation of the Chinese version of obsessive-compulsive inventory-revised","volume":"29","author":"Hon","year":"2019","journal-title":"East Asian Arch Psychiatry"},{"key":"B25","doi-asserted-by":"publisher","first-page":"476","DOI":"10.3969\/j.issn.1000-6729.2011.06.014","article-title":"Reliability and validity of the Chinese version of Beck Depression Inventory-II among depression patients","volume":"6","author":"Wang","year":"2011","journal-title":"Chin Ment Health J."},{"key":"B26","doi-asserted-by":"publisher","first-page":"321","DOI":"10.3969\/j.issn.1002-0829.2006.06.001","article-title":"The reliability and validity of the Chinese version of Yale-Brown obsessive-compulsive scale","volume":"18","author":"Xu","year":"2006","journal-title":"Shanghai Arch Psychiatry"},{"key":"B27","first-page":"447","article-title":"Validation of the Chinese Version of Beck Anxiety Inventory","volume":"10","author":"Che","year":"","journal-title":"Taiwan Medical Journal 2006"},{"key":"B28","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1016\/S0163-7258(99)00048-0","article-title":"Pharmacokinetics of selective serotonin reuptake inhibitors","volume":"85","author":"Hiemke","year":"2000","journal-title":"Pharmacol Ther."},{"key":"B29","doi-asserted-by":"publisher","first-page":"1752","DOI":"10.1001\/jama.280.20.1752","article-title":"Sertraline in children and adolescents with obsessive-compulsive disorder: a multicenter randomized controlled trial","volume":"280","author":"March","year":"1998","journal-title":"JAMA."},{"key":"B30","doi-asserted-by":"publisher","first-page":"80","DOI":"10.1002\/wps.20299","article-title":"Towards an international expert consensus for defining treatment response, remission, recovery and relapse in obsessive-compulsive disorder","author":"Mataix-Cols","year":"2016","journal-title":"World Psychiatry."},{"key":"B31","doi-asserted-by":"publisher","first-page":"850","DOI":"10.1038\/mp.2009.50","article-title":"Meta-analysis of the dose-response relationship of SSRI in obsessive-compulsive disorder","volume":"15","author":"Bloch","year":"2010","journal-title":"Mol Psychiatry."},{"key":"B32","doi-asserted-by":"publisher","first-page":"15","DOI":"10.4088\/JCP.v67n0103","article-title":"High-dose sertraline strategy for nonresponders to acute treatment for obsessive-compulsive disorder: a multicenter double-blind trial","volume":"67","author":"Ninan","year":"2006","journal-title":"J Clin Psychiatry."},{"key":"B33","doi-asserted-by":"publisher","first-page":"261","DOI":"10.1080\/17425255.2019.1584611","article-title":"Dell'Osso L","author":"Marazziti","year":"2019","journal-title":"Pharmacokinetics of serotonergic drugs: focus on OCD Expert Opin Drug Metab Toxicol."},{"key":"B34","doi-asserted-by":"publisher","first-page":"e2686","DOI":"10.1002\/hup.2686","article-title":"Treatments used for obsessive-compulsive disorder-an international perspective","volume":"34","author":"Brakoulias","year":"2019","journal-title":"Hum Psychopharmacol."},{"key":"B35","doi-asserted-by":"publisher","first-page":"568","DOI":"10.1097\/01.jcp.0000095342.32154.54","article-title":"A double blind comparison of venlafaxine and. paroxetine in obsessive-compulsive disorder","volume":"23","author":"Denys","year":"2003","journal-title":"J Clin Psychopharmacol."},{"key":"B36","doi-asserted-by":"publisher","first-page":"82","DOI":"10.1097\/JCP.0000000000000989","article-title":"Effectiveness of venlafaxine in selective. serotonin reuptake inhibitor-resistant obsessive-compulsive disorder: experience from a specialty clinic in India","volume":"39","author":"Balachander","year":"2019","journal-title":"J Clin Psychopharmacol."},{"key":"B37","doi-asserted-by":"publisher","first-page":"112602","DOI":"10.1016\/j.psychres.2019.112602","article-title":"A systematic review and meta-analysis: Memantine augmentation in moderate to severe obsessive-compulsive disorder","volume":"282","author":"Modarresi","year":"2019","journal-title":"Psychiatry Res."},{"key":"B38","doi-asserted-by":"publisher","first-page":"19f13163","DOI":"10.4088\/JCP.19f13163","article-title":"Augmentation with memantine in obsessive-compulsive disorder","volume":"80","author":"Andrade","year":"2019","journal-title":"J Clin Psychiatry"},{"key":"B39","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1080\/14656566.2018.1540590","article-title":"A systematic review of the use of risperidone, paliperidone and. aripiprazole as augmenting agents for obsessive-compulsive disorder","volume":"20","author":"Brakoulias","year":"2019","journal-title":"Expert Opin Pharmacother."},{"key":"B40","volume-title":"Guideline Watch: Practice Guideline for the Treatment of Patients. With Obsessive-Compulsive Disorder","author":"Simpson","year":"2013"},{"key":"B41","first-page":"526","article-title":"Risperidone addition in fluvoxamine- refractory obsessive-compulsive disorder: three cases","volume":"56","author":"McDougle","year":"1995","journal-title":"J Clin Psychiatry."},{"key":"B42","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1097\/JCP.0b013e318192e9a4","article-title":"Memantine augmentation in treatment-resistant obsessive-compulsive disorder: an open-label trial","volume":"29","author":"Aboujaoude","year":"2009","journal-title":"J Clin Psychopharmacol."},{"key":"B43","doi-asserted-by":"publisher","first-page":"265","DOI":"10.1097\/YIC.0b013e32832e9b91","article-title":"Aripiprazole augmentation of serotonin reuptake inhibitors in treatment-resistant obsessive-compulsive disorder: a 12-week open-label preliminary study","volume":"24","author":"Pessina","year":"2009","journal-title":"Int Clin Psychopharmacol."},{"key":"B44","doi-asserted-by":"publisher","first-page":"148","DOI":"10.1097\/00004714-200204000-00007","article-title":"Sertraline and fluoxetine treatment of obsessive-compulsive disorder: results of a double-blind, 6-month treatment study","author":"Bergeron","year":"2002","journal-title":"J Clin Psychopharmacol."},{"key":"B45","article-title":"Clinical global impressions","volume-title":"ECDEU Assessment Manual for Psychopharmacology, Revised","author":"Eds","year":""},{"key":"B46","doi-asserted-by":"publisher","first-page":"561","DOI":"10.1001\/archpsyc.1961.01710120031004","article-title":"An inventory for measuring depression","volume":"4","author":"Beck","year":"1961","journal-title":"Arch Gen Psychiatry."},{"key":"B47","volume-title":"Assessment Manual for Psychopharmacology.","author":"ECDEU","year":"1976"},{"key":"B48","doi-asserted-by":"publisher","first-page":"e007768","DOI":"10.1136\/bmjopen-2015-007768","article-title":"Comparative efficacy and tolerability of first-generation and newer-generation antidepressant medications for depressive disorders in children and adolescents: study protocol for a systematic review and network meta-analysis","volume":"5","author":"Zhou","year":"2015","journal-title":"BMJ Open."}],"container-title":["Frontiers in Psychiatry"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fpsyt.2022.822976\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,5,16]],"date-time":"2022-05-16T14:12:50Z","timestamp":1652710370000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fpsyt.2022.822976\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,5,16]]},"references-count":48,"alternative-id":["10.3389\/fpsyt.2022.822976"],"URL":"https:\/\/doi.org\/10.3389\/fpsyt.2022.822976","relation":{},"ISSN":["1664-0640"],"issn-type":[{"value":"1664-0640","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,5,16]]},"article-number":"822976"}}